多发性骨髓瘤免疫治疗的演变现状:双特异性抗体的未来角色
该综述指出,多发性骨髓瘤(MM)过去十年疗效显著改善,但高危患者(R-ISS III期、不良细胞遗传学、对蛋白酶体抑制剂/免疫调节剂/单克隆抗体难治)结局仍差。MM特征为免疫功能障碍和肿瘤允许性免疫微环境,免疫治疗正快速发展;本文聚焦双特异性抗体(BsAb),综述已发表临床试验的疗效、安全性(细胞因子释放综合征和免疫效应细胞相关神经毒性综合征)及其与CAR-T的比较,讨论靶点及未来治疗定位。
要点
- 高危MM患者(R-ISS III期、不良细胞遗传学、三重难治)结局差,是未满足的临床需求。
- BsAb是MM免疫治疗的重要方向,需关注CRS和ICANS风险并与CAR-T比较。
- 综述汇总已发表临床试验的疗效和安全性,并探讨BsAb在MM治疗范式中的定位。
核心结论
- MM免疫治疗快速发展,BsAb是重要方向,但高危患者仍存在 urgent 未满足需求。
研究设计与样本
- 本文为综述,聚焦MM中双特异性抗体(BsAb)的临床与临床前进展,并回顾已发表临床试验的疗效和安全性数据。
主要发现
- 高危MM患者包括R-ISS III期、不良细胞遗传学或对蛋白酶体抑制剂、免疫调节药物和单克隆抗体难治者,结局可能很差。
- MM特征为免疫功能障碍和肿瘤允许性免疫微环境,改善免疫麻痹可能改善结局。
- BsAb的疗效和安全性(尤其CRS和ICANS)需与CAR-T比较,靶点包括临床和临床前阶段。
临床怎么用
- 关注BsAb在MM中的疗效和安全性,特别是CRS和ICANS的管理,并考虑与CAR-T的差异。
- 根据高危因素(R-ISS III期、不良细胞遗传学、三重难治)识别可能从BsAb获益的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment outcomes in multiple myeloma (MM) have improved dramatically over the past 10 years. However, patients with high-risk disease such as those with Stage III disease by the Revised International Staging System, the presence of adverse cytogenetics, or who are refractory to proteosome inhibitors, immunomodulatory drugs and monoclonal antibodies may have dismal outcomes. These patients represent an urgent ongoing need in MM. One of the hallmarks of MM is immune dysfunction and a tumour-permissive immune microenvironment. Ameliorating the immune-paresis could lead to improved outcomes. The role of immunotherapies has been growing at an exponential pace with numerous agents under development in clinical trials. In the present review, we provide an overview of immunotherapies in MM, focussing on bispecific antibodies (BsAbs). We review efficacy outcomes from the published clinical trials and consider the important safety aspects of these therapies, in particular the risk of cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome, and how these compare with patients receiving chimeric antigen receptor T cells. We discuss the MM epitopes being targeted by BsAbs, either in clinical or preclinical stages, and we consider where these therapies might best fit within the future ever-changing paradigm of MM treatment.
引用
- Swan D, Routledge D, Harrison S, et al. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. Br J Haematol. 2021. PMID: 34472091. doi:10.1111/bjh.17805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。